Innate Pharma Gains FDA Clearance for Lacutamab Phase 3, Holds $44.8M Cash
Innate Pharma obtained FDA clearance to start its Telemax phase 3 lacutamab trial in CTCL in H2 2026 and expects monalizumab Pacific 9 data readout with AstraZeneca also in H2 2026. It holds $44.8M cash through Q3 2026 but posted $63M operating expenses against $9M revenue.
1. FDA Clearance for Telemax Phase 3 Trial
Innate Pharma secured FDA clearance to initiate its Telemax phase 3 lacutamab trial in CTCL, with dosing expected to begin in the second half of 2026. This milestone follows successful phase 2 results and positions lacutamab for pivotal clinical evaluation.
2. Early Signs from IPH 4,502 Program
The IPH 4,502 ADC has demonstrated preliminary anti-tumor activity in heavily pretreated urothelial cancer patients while maintaining a favorable safety profile. As a Topo1-based ADC targeting nectin 4, it addresses a gap in the post-PAD therapeutic setting.
3. Monalizumab Pacific 9 Partnership Update
In partnership with AstraZeneca, monalizumab is advancing toward a Pacific 9 phase 3 data readout slated for H2 2026, reinforcing its role in innate immunity modulation. A shift of project management to AstraZeneca has reduced collaboration revenue but underscores program maturity.
4. Financial Position and Cost Structure
The company holds $44.8M in cash, providing visibility to fund operations until the end of Q3 2026, while reporting $63M in operating expenses and only $9M in revenue. Management is evaluating financing options to support upcoming phase 3 development costs.